ClinicalTrials.gg
RecruitingNCT07571551TRIPLE-PATHUpdated May 11, 2026

Perioperative Trial With IO/TKI for Multi-stage Clear Cell Renal Cell Carcinoma

A Phase 2 interventional study of Toripalimab and Lenvatinib in Clear Cell RCC, sponsored by Jinling Hospital, China. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-05-11.

Sponsored by Jinling Hospital, China · Phase 2, Interventional, and Treatment

How we know · 5 judgments

From the registry’s dates

  • Started May 2026; still recruiting 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
75
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies testing toripalimab in Carcinoma, Renal Cell — 8 open to participants now, 11 under way, 1 of them phase 3. toripalimab · Carcinoma, Renal Cell.

Planned enrollment
3rd of 13
75 · median 40
Started
2026
with 4 others
Phase 2
11 of 13
6 open now
Primary completion
2027-12
later than 4 of 10 live
Registered
10th of 13
by date
Lead sponsor
2 of 13
Jinling Hospital, China

Among the 13 studies testing toripalimab in Carcinoma, Renal Cell, this one is the 3rd largest by planned enrollment, is one of 5 that started in 2026, is one of 11 in phase 2, reaches primary completion later than 4 of the 10 other live ones, and was the 10th registered.

Carcinoma, Renal Cell

2,043 studies on the registry are indexed under Carcinoma, Renal Cell; 395 are open to participants now.

Browse Carcinoma, Renal Cell studies →

Open to participants now

8 of the 13 studies testing toripalimab in Carcinoma, Renal Cell are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

About toripalimab

toripalimab: first FDA approval 2023 (LOQTORZI), first EMA approval 2024. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 308 Carcinoma, Renal Cell studies recruiting now, 255 (83%) set no upper age limit and 18 (6%) stop at 75 or younger; 21 take children under 18; 20 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies testing toripalimab in Carcinoma, Renal Cell, or all of them as a file.
02

Study summary

The IO/TKI regimens which combines Immune checkpoint inhibitors (IO) with Tyrosine Kinase Inhibitors (TKI) have become the standard first-line option for advanced ccRCC. Currently, IO/TKI regimens are serving as neoadjuvant treatment in arising clinical trials for ccRCC. Although anatomical change reflected by radiological response is reported in most neoadjuvant trials, only few studies focus on evaluation for pathological response in ccRCC.

The TRIPLE-PATH trial is an investigator initiated prospective, open-label phase II trial with the main objective to evaluate the clinical activity of preoperative/neoadjuvant therapy of toripalimab plus lenvatinib as mesured by pathological response of resected primary lesion in multi-stage ccRCC. Patients with ccRCC will be enrolled into 3 different cohorts based on their clinical TNM at the time of screening: localized ccRCC (cT1-2N0M0), locally advanced ccRCC (cT3-4N0M0 or cTanyN1M0), and metastatic ccRCC (cTanyNanyM1). Toripalimab (240mg Q3W) will be administered intravenously on the 1st day, and lenvatinib (20mg QD) will be administered orally once daily of each 3 weeks cycle. Patients in all cohorts will receive 4 cycles of preopertive/neoadjuvant toripalimab (240mg Q3W IV) plus lenvatinib (20mg QD PO), and a subsequent partial/radical nephrectomy 7-10 days after the last cycle. For adjuvant/postoperative treatment, patients who undergo R0 resection presented with cT1-2aN0M0G4/cT2bN0M0G3-4/cT3-4N0M0Gany/cTanyN1M0Gany will receive adjuvant doses of toripalimab (240mg Q3W IV) for 17 cycles; patients who undergo simultaneous resection of all oligometastases considered as "no evidence of disease" (M1 NED) will also receive adjuvant doses of toripalimab (240mg Q3W IV) for 17 cycles; patients who undergo R1 resection or presented with M1 disease cannot be definitely resected will receive postoperative doses of toripalimab (240mg Q3W IV) plus lenvatinib (20mg QD PO) for 17 cycles.

Specific follow-up for the enrolled patients is required in the TRIPLE-PATH trial. Longitudinal CT/MRI is utilized to assess the radiological response. Tissues and body fluid samples collected from the patients will be utilized for biomarker and multi-omic analysis.

The primary endpoint of the TRIPLE-PATH trial is major pathological response (MPR) in the primary lesion according to the pathological response reporting guidelines by the International Neoadjuvant Kidney Cancer Consortium (INKCC). Simon's two-stage minimax design is adopted by TRIPLE-PATH. An initial of 12 patients per cohort (36 in total) will be recruited, following an interim analysis. Recruitment to any cohort will be suspended if MPR is not observed in any patient at the interim analysis. If MPR is observed in at least 1 patient, additional 9 patients will be recruited in each cohort to at most 21 patients. Considering potential 15% dropout rate in each cohort, an anticipation of 25 patients will be recruited for each cohort (75 in total) in this study.

03

Conditions studied

  • Clear Cell RCC

Keywords

  • ccRCC
  • Immunotherapy
  • Tyrosine Kinase Inhibitors
  • pathologic response
  • Nephrectomy
  • Perioperative
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients have fully understood and give written prior to receive therapy. Patients with history of major psychiatric disease must be judged able to fully understand the trial, and the explicit consent of family members is required;
  • Patients with the ages range from 18 to 80 years old (at the time of signing informed consent);
  • (ECOG) Performance Status 0 or 1;
  • Patients have at least 1 measurable target lesion according to v1.1. The target lesion can be biopsied as per protocol.
  • confirmed clear cell RCC;
  • Patients will be enrolled into 3 separate cohorts based on their clinical TNM at the time of baseline screening:

    1. Cohort 1: localized ccRCC (cT1-2N0M0): the primary tumor in this cohort must meet the subsequent criteria:

      • The cT1a primary tumor should have ≥10 R.E.N.A.L. score, or locate in renal hilum close to renal artery or its main branch;

        • Patients with cT1b-2b primary tumors can be directly enrolled;

          • In case of necessary, patients will undergo dual radiological examinations using contrast-enhanced CT and MRI to rule out potential invasion of the renal pelvis or perirenal fat as per protocol.
    2. Cohort 2: locally advanced ccRCC (cT3-4N0M0 or cTanyN1M0);
    3. Cohort 3: ccRCC (cTanyNanyM1): the patients should be evaluated as suitable for cytoreductive nephrectomy.

      • Patient have no symptomatic metastatic lesions requiring urgent intervention;

        • The sum of the diameters of the other target lesions (excluding the primary tumor) does not exceed the longest diameter of the primary tumor.
  • The patients who are treatment-naive, and have not received systemic therapy for any tumor;
  • Adequate main organ function. The screening laboratory indicators must meet the following criteria:

    1. ≥ 90 g/L (Without blood transfusion);
    2. count ≥ 100 x 109/L;
    3. ≥ 1.5 x 109/L;
    4. Serum creatinine ≤ 1.5 x , or > 60 mL/min/1.73m2;
    5. Total ≤ 1.5 mg/dL;
    6. (AST) and/or alanine aminotransferase (ALT) ≤ 2.5 x ULN for patients without evidence of liver metastases; AST and/or ALT ≤ 5 x ULN for patients with liver metastases;
    7. Normal CK;
    8. Normal Troponin T;
    9. Normal LDH.
  • Willingness and ability to comply with planned visits, therapeutic laboratory testing, and other procedures.

Exclusion criteria

Exclusion Criteria:

  • Signs of tumor involving the central nervous system, or radiological evidence of ;
  • History of malignant tumors other than ccRCC within the previous 5 years, with the exception of malignant tumors that can be expected to be cured with treatment (including but not limited to adequately treated thyroid cancer, carcinoma in situ of the cervix, basal or squamous cell skin cancer, or ductal carcinoma in situ of the breast treated with radical surgery);
  • Prior to participating in the study, patients have received prior , drugs or device therapy;
  • History of undergoing major surgery (judged by the investigator) within 4 weeks before the first trial dose, are recovering, or are unable to undergo baseline puncture;
  • History of severe drug allergy, including but not limited to antibody drugs;
  • Patients with to immunotherapy restart, including but not limited to:

    1. Grade 2-4 immune myocarditis;
    2. Severe grade 4 proteinuria;
    3. Severe or life-threatening grade 4 immune hepatitis;
    4. Severe grade 3-4 immune pneumonitis;
    5. Severe inflammatory arthritis that significantly affects daily life or quality of life;
    6. Severe neurological toxicity:
    7. Myasthenia gravis grade 2-4;
    8. Guillain-Barre syndrome (GBS) or transverse myelitis of any grade;
    9. Grade 2-4 encephalitis;
    10. Severe or life-threatening grade 3-4 pancreatitis;
    11. Severe or life-threatening bullous disease (grade 3-4);
    12. Severe grade 3-4 uveitis or episcleritis.
  • Known history of allogeneic organ transplantation or hematopoietic stem cell transplantation or long-term therapy.
  • Non-resolution of toxicity after previous antineoplastic therapy, i.e., resolution to baseline, v5.0 grade 0-1 (excluding alopecia), or inclusion/exclusion criteria. Irreversible toxicities (e.g., hearing loss) that would not reasonably be expected to be exacerbated by the study drug can be included in the study;
  • Known history of liver disease, including active viral hepatitis ( surface antigen (HBsAg) and/or hepatitis B core antibody (HbcAb) positive, HBV DNA>10000 copies /mL or >2000 IU/mL; virus (HCV) antibody positive and HCV RNA positive), or other active hepatitis, clinically significant moderate to severe cirrhosis;
  • Patients with uncontrolled third space effusion requiring repeated drainage, such as pleural effusion, ascites, pericardial effusion, etc. (Patients who do not need drainage of effusion or stop drainage for 3 days without significant increase in effusion can be enrolled);
  • Receiving a systemic corticosteroid (prednisone > 10mg/ day or equivalent) or other medication within 14 days before the first study medication;
  • Patients with any severe and/or uncontrolled disease, including:

    1. Hypertension that is not well controlled by antihypertensive medication;
    2. Unstable angina pectoris or myocardial infarction, coronary artery bypass grafting or stent implantation within 6 months before study medication;
    3. Grade I or above myocardial ischemia or myocardial infarction, arrhythmia (including ≥480ms) and ≥ grade 2 congestive heart failure ( (NYHA) classification); Degree II or above heart block; (LVEF) \< 50%;
    4. Poorly controlled diabetes (fasting blood glucose > 10 mmol/L);
    5. Patients with urinary protein ≥++ and confirmed 24-hour urinary protein > 1.0g;
    6. Severe active or uncontrolled infection.
  • Patients with or suspected to have active diseases, including but not limited to systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, etc.;
  • Renal failure requiring hemodialysis or peritoneal dialysis;
  • Patients with a history of immunodeficiency, including positive patients, other acquired immunodeficiency diseases, congenital immunodeficiency diseases, or organ transplantation history;
  • History of inoculation within 4 weeks before the first study drug or the expected vaccination during the study period;
  • History of psychiatric drug abuse and can not quit or have a history of mental disorders;
  • Women who are of . Women of childbearing potential must have a negative serum or urine pregnancy test, and must use appropriate methods of .
  • The presence of any other severe, acute or chronic medical disease or mental illness or laboratory abnormality, as judged by the investigator, that may increase the risk associated with participation in the study or that may interfere with the interpretation of the results of the study.
Terms in these criteria, in plain language(32)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
75 participants (estimated)

Study arms

  • Experimental
    Experimental: Perioperative toripalimab + lenvatinib followed by a partial/radical nephrectomy

    Toripalimab (240mg Q3W) will be administered intravenously on the 1st day of each 3 weeks cycle, and lenvatinib (20mg QD) will be administered orally once daily of each 3 weeks cycle. The patients will receive preoperative/neoadjuvant 4 cycles of toripalimab (240mg Q3W IV) plus lenvatinb (20mg QD PO) followed by a partial/radical nephrectomy 7-10 days after the last cycle. Adjuvant 17 cycles of toripalimab (240mg Q3W IV) will start at 4-8 weeks after surgery, for patients who undergo R0 resection but presented with cT1-2aN0M0G4/cT2bN0M0G3-4/cT3-4N0M0Gany/cTanyN1M0Gany, or undergo simultaneous resection of all oligometastases considered as "no evidence of disease" (M1 NED). Postoperative 17 cycles of toripalimab (240mg Q3W IV) plus lenvatinb (20mg QD PO) will start at 4-8 weeks after surgery, for patients who undergo R1 resection or presented with M1 disease cannot be definitely resected.

    Drug: Toripalimab · Drug: Lenvatinib

Interventions

  • Patients will receive 4 cycles of preoperative/neoadjuvant toripalimab (240mg Q3W IV) followed by a partial/radical nephrectomy 7-10 days after the last cycle. Patients who undergo R0 resection but presented with cT1-2aN0M0G4/cT2bN0M0G3-4/cT3-4N0M0Gany/cTanyN1M0Gany, or undergo simultaneous resection of all oligometastases considered as "no evidence of disease" (M1 NED), will receive 17 cycles of adjuvant toripalimab (240mg Q3W IV), starting at 4-8 weeks after surgery. Patients who undergo R1 resection or presented with M1 disease cannot be definitely resected will receive 17 cycles of postoperative toripalimab (240mg Q3W IV), starting at 4-8 weeks after surgery. Adjustment of dose: For patients with grade 3 or greater adverse events according to CTCAE v5.0 suspected to be caused by toripalimab, the dose can be postponed. In case of SAE, the dose can be discontinued. Dose de-escalation can be decided in patients who achieve MPR in primary lesions by investigators as per protocol.

    Also known as: anti-PD-1 monoclonal antibody

  • Patients will receive 4 cycles of preoperative/neoadjuvant lenvatinib (20mg QD PO) of each 3 weeks cycle followed by a partial/radical nephrectomy 7-10 days after the last cycle. Patients who undergo R1 resection or presented with M1 disease cannot be definitely resected will receive 17 cycles of postoperative lenvatinib (20mg) orally once daily of each 3 weeks cycle, starting at 4-8 weeks after surgery. Adjustment of dose: For patients with grade 3 or greater adverse events according to CTCAE v5.0 suspected to be caused by lenvatinib, the dosage can be gradually reduced to 16mg, 12mg and a minimal of 8mg. In case of SAE, the dose can be discontinued. Dose de-escalation can be decided in patients who achieve MPR in primary lesions by investigators as per protocol.

    Also known as: Lenvatinib mesylate (USAN), Multi-Kinase Inhibitor

06

What researchers measure

Primary outcomes

  1. Major Pathological Response Rate

    MPR is defined as the total proportion of viable residual tumor cells in the tumor bed via H-E stained sections of the resected tumor according to the guidelines by INKCC. Major pathological response rate is defined as the proportion of patients achieving MPR in their primary lesion.

    Time frame: Within 1 week after nephrectomy

Secondary outcomes

  1. Safety according to Adverse Events

    The frequency and percentage of patients experiencing adverse events (AEs) according to Common Terminology Criteria for Adverse Events version 5.0 (CTCAE v5.0).

    Time frame: From baseline to 12 weeks after last dose

  2. Surgical morbidity

    Surgical morbidity or complications rate after neoadjuvant therapy. Intraoperative adverse incidents are defined as adverse events due to surgical intervention occurring between skin incision and closure and are evaluated according to the EAU intraoperative AI classification (EAUiaiC). Postoperative complications are evaluated according to Clavien-Dindo classification system.

    Time frame: Up to 4 weeks after nephrectomy

  3. Best Overall Response

    BOR is defined as the best response state among all the longitudinal evaluation according to RECIST v1.1. A modified BOR only focusing on metastases will be specially utilized for patients in cohort 3.

    Time frame: From baseline to 12 weeks

  4. Down-staging Rate of Primary T Stage

    The T stage of the primary lesion will be evaluated according to the 8th edition of AJCC at baseline and surgery to reflect the change in T stage of the primary lesion after neoadjuvant therapy.

    Time frame: From baseline to 12 weeks

  5. Change in R.E.N.A.L. Score of Primary Lesion

    The R.E.N.A.L. score can reflect the difficulty of the nephrectomy. The R.E.N.A.L. scores of the patients before and after neoadjuvant therapy will be evaluated based on the CT/MRI scan.

    Time frame: From baseline to 12 weeks

  6. Rate of R0 Resection

    R0 resection is defined as no visible tumor cells were observed at the surgical margins of the pathological specimens.

    Time frame: Within 1 week after nephrectomy

  7. Change in Tumor Thrombus

    For patients with TT at baseline, the change of TT according to Mayo's classification will be recorded.

    Time frame: From baseline to 12 weeks

  8. Change in Renal Function

    The change in renal function before and after neoadjuvant therapy,also before and after nephrectomy will be evaluated by eGFR. The eGFR will be calculated using the CKD-EPI formula. Split renal function recovery rate will be report in patients who undergo partial nephrectomy.

    Time frame: Up to 1 year after nephrectomy

  9. Progression Free Survival

    PFS is defined as the time from enrollment to progression disease, recurrence, distant metastasis or death from any cause.

    Time frame: Up to 5 years after treatment

  10. Disease Free Survival

    DFS is defined as the time from completion of nephrectomy to recurrence, distant metastasis or death from any cause. DFS will only be reported in the cohort 1 and 2.

    Time frame: Up to 5 years after nephrectomy

  11. Overall Survival

    OS is defined as the time from enrollment to death from any cause.

    Time frame: Up to 5 years after treatment

Other outcomes

  1. Tissue-based Biomarker Analysis

    Biopsied and resected tumor specimens will be collected for revealing changes in the tumor microenvironment.

    Time frame: Up to 2 years after treatment

  2. Peripheral Plasma-based Biomarker Analysis

    Baseline, during-treatment, pre-operative, and postoperative peripheral plasma will be collected for revealing potential cycling biomarkers.

    Time frame: Up to 2 years after treatment

  3. Radiological and Pathological Biomarker Analysis

    The radiological and pathological information during the treatment process will be collected. A prediction model related to therapeutic efficacy and prognosis is anticipated to be developed.

    Time frame: Up to 2 years after treatment

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Dec 2027, 19 months after the start.

Of 185 non-industry phase 2 interventional studies under Carcinoma, Renal Cell, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 98. This study's planned 19 months is below that.

Counting every sponsor, half of 232 studies reached it within 58 months; a quarter within 33 and three quarters within 94.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 22, 2026
First posted
May 6, 2026
StartActual
May 6, 2026
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2032
Last update
May 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07571551
Responsible party
Le Qu (Associate chief urologist, Jinling Hospital, China) — Principal investigator
First posted
May 6, 2026
Start date
May 6, 2026
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2032 (estimated)
Last update
May 11, 2026

Study contacts

Le Qu, M.D.
Contact
septsoul@hotmail.com
+86 15720625951
Le Qu, M.D.
principal investigator · Jinling Hospital, China

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Toripalimab · Lenvatinib

Start the discussion